NN&I - April 2010
Patient Management www.nephronline.comApril 2010 Nephrology News & Issues 35 balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol. 1999;10:2029-2043. 17. Agarwal R. Overcoming barriers that inhib- it proper treatment of anemia. Kidney Int. 2006;(suppl):S9-12 18. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombi-nant human erythropoietin. Kidney Int. 2005;68: 1337-1443 19. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif. 2004;22:112-123 20. Gilbertson DT, Ebben James P, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol. 2008;3:133-138. 21. Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitaliza-tions. Clin J Am Nephrol. 2006;1:1205-1210 22. Singh AK, Milford E, Fishbane S, et al. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int. 2008;74:679-683 23. Canavese C, Grill A, DeCostanzi E, et al. How to save money for erythropoietin therapy by changing from 'roller coaster' to continuous iron supplemen-tation. Nephron. 1999;81:362-363 24. Senger JM, Weiss RJ. Hematologic and eryth- ropoietin responses to iron dextran in the hemodi-alysis environment. ANNA J. 1996;23:319-323 25. Bola\361os L, Castro P, Falcon TG, et al. Continuous intravenous sodium ferric gluconate improves effi-cacy in the maintenance phase of EPOrHu admin-istration in hemodialysis patients. Am J Nephrol. 2002;22:67-72 26. Taylor JE, Peat N, Porter C, et al. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1079-1083 27. Kwack C, Vaidyanathapuram S. Managing erythropoietin hyporesponsiveness. Semin Dial. 2006;19:146-151 28. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995;10:2070-2076 29. Sepandj F, Jindal K, West M, Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant. 1996;11:319-32230. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac dis-ease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-59031. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181-1191 32. Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866-876 33. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-a dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791-79834. Aranesp® (darbepoietin alfa) prescribing infor -mation. Amgen, Inc. Thousand Oaks, Calif. 2008. 35. Procrit® (epoetin alfa) prescribing infor- mation. Ortho Biotech Products, L.P. Raritan, NJ. 200836. Epogen® (epoetin alfa) prescribing informa- tion. Amgen, Inc. Thousand Oaks, Calif. 2008 37. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative throm-bocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2008;52:727-736 38. van Riemsdijk IC, Baan CC, Loonen EH, et al. T cells activate the tumor necrosis factor-alpha system during hemodialysis, resulting in tachyphy-laxis. Kidney Int. 2001,59:883-892 39. Weiss G, Meusburger E, Radacher G, et al. Effect of iron treatment on circulating cytokine lev-els in ESRD patients receiving recombinant human erythropoietin. Kidney Int. 2003,64:572-578 40. Besarab A, Amin N, Ashan M, et al. Optimization of epoetin therapy with intravenous iron thera- py in hemodialysis patients. J Am Soc Nephrol. 2000;11:530-538 41. Leavitt MO: Secretary of Health and Human Services Report to Congress: A design for a bundled end-stage renal disease prospective pay-ment system, 2008. Available at: http://www. cms.hhs.gov/ESRDGeneralInformation/Downloads/ ESRDReportToCongress.pdf 42. Wish JB. Past, present, and future of chronic kidney disease anemia management in the United States. Adv Chronic Kidney Dis. 2009;16:101-108. 43. Coyne DW, Sims A, Bingel B. Results of an ane-mia management program to reduce high Epoetin doses by targeted use of IV Ferric Gluconate. Nephrol Nurs J. 2008;35:1-5 Patient Management_0410_7.indd 35 3/18/10 3:48:07 PM
You must have JavaScript enabled to view digital editions.
